Advertisement
Advertisement
U.S. markets open in 2 hours 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Exact Sciences Corporation (EXAS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
80.84+4.25 (+5.55%)
At close: 04:00PM EST
80.84 0.00 (0.00%)
After hours: 07:53PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close76.59
Open76.18
Bid0.00 x 1000
Ask0.00 x 800
Day's Range73.41 - 81.25
52 Week Range73.41 - 159.54
Volume1,780,013
Avg. Volume1,545,903
Market Cap13.93B
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-4.89
Earnings DateFeb 14, 2022 - Feb 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est132.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EXAS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exact Sciences Corporation
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening.
    Rating
    Fair Value
    Economic Moat
    19 days agoMorningstar
View more
Advertisement
Advertisement